Search results
ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues
Zacks via Yahoo Finance· 6 months agoImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong...
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance· 2 years agoImmunoGen, Inc. IMGN incurred a loss of 24 cents per share for second-quarter 2022, wider than the...
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
Zacks via Yahoo Finance· 12 months agoImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for...
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat...
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
Zacks via Yahoo Finance· 9 months agoImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The...
ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors
Zacks via Yahoo Finance· 10 months agoImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a...
Wall Street Analysts Think ImmunoGen (IMGN) Could Surge 49.11%: Read This Before Placing a Bet
Zacks via Yahoo Finance· 7 months agoThe mean of analysts' price targets for ImmunoGen (IMGN) points to a 49.1% upside in the stock....
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug
Zacks via Yahoo Finance· 1 year agoImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx,...
ImmunoGen (IMGN) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance· 2 years agoImmunoGen (IMGN) delivered earnings and revenue surprises of -19.23% and 30.16%, respectively, for...
With 72% institutional ownership, ImmunoGen, Inc. (NASDAQ:IMGN) is a favorite amongst the big guns
Simply Wall St. via Yahoo Finance· 1 year agoEvery investor in ImmunoGen, Inc. (NASDAQ:IMGN) should be aware of the most powerful shareholder...